{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:35:05Z","timestamp":1792773305988,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01069-w","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:47:55Z","timestamp":1792766875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6274-5982","authenticated-orcid":false,"given":"Ito","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1069_CR1","unstructured":"ICH Expert Working Group. Ethnic factors in the acceptability of foreign clinical data E5(R1). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1998. Accessed 9 June 2026. https:\/\/database.ich.org\/sites\/default\/files\/E5_R1__Guideline.pdf"},{"key":"1069_CR2","unstructured":"Ministry of Health, Labour and Welfare (MHLW), Japan. Basic principles on global clinical trials. Notification No. Yakushokushinsa-hatsu 0928010; 2007."},{"key":"1069_CR3","unstructured":"ICH Expert Working Group. General principles for planning and design of multi-regional clinical trials E17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2017. Accessed 9 June 2026. https:\/\/database.ich.org\/sites\/default\/files\/E17EWG_Step4_2017_1116.pdf"},{"issue":"2","key":"1069_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/2168479016672702","volume":"51","author":"A Hirakawa","year":"2017","unstructured":"Hirakawa A, Kinoshita F. An analysis of Japanese patients enrolled in multiregional clinical trials in oncology. Ther Innov Regul Sci. 2017;51(2):207\u201311.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"1069_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cpt.3456","volume":"117","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Narukawa M. New drug development strategy in Japan: flexibility in guideline adherence. Clin Pharmacol Ther. 2025;117(1):270\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1069_CR6","first-page":"5","volume":"16","author":"A Hasegawa","year":"2026","unstructured":"Hasegawa A, Sera S, Nagai N. Analysis of sample size allocation to Japan and primary endpoint in confirmatory multiregional clinical trials for oncology drug development. Regul Sci Med Prod. 2026;16(1):5\u201320.","journal-title":"Regul Sci Med Prod"},{"issue":"4","key":"1069_CR7","first-page":"245","volume":"22","author":"A Schuhmacher","year":"2023","unstructured":"Schuhmacher A, Gassmann O, Hinder M. The rise of external innovation: how big pharma is sourcing new drugs. Nat Rev Drug Discov. 2023;22(4):245\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1069_CR8","unstructured":"IQVIA Global Trends in R&D 2025. IQVIA Institute; 2025."},{"key":"1069_CR9","unstructured":"Council of the Concept for Early Prevalence of the Novel Drugs to Patients by Improving Drug Discovery Capabilities. Interim Report: Establish a Top-Level Drug Discovery Site That Contributes to the Health of People Worldwide. Cabinet Secretariat of Japan; 2026. Accessed 9 June 2026. https:\/\/www.cas.go.jp\/jp\/seisaku\/souyakuryoku\/pdf\/interim_report.pdf"},{"key":"1069_CR10","volume":"65","author":"WJ Jean Yeung","year":"2025","unstructured":"Jean Yeung WJ, Abalos JB. Social determinants of low fertility in Asia: a comparative review of trends in East, Southeast and South Asia. Lancet Reg Health West Pac. 2025;65:101724.","journal-title":"Lancet Reg Health West Pac"},{"key":"1069_CR11","unstructured":"Ministry of Health, Labour and Welfare. Basic Principles on Japanese Clinical Trial Data for Drugs for Rare Diseases, etc., for Which Confirmatory Clinical Trials Have Been Conducted Only Overseas. PMSB\/ELD Notification No. 1023\u20133. 2024. Accessed 9 June 2026. https:\/\/www.pmda.go.jp\/files\/000275134.pdf"},{"issue":"5","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s43441-024-00639-0","volume":"58","author":"R Singh","year":"2024","unstructured":"Singh R, Wang W, Chakravarty A, Wang J, Uyama Y. Simultaneous global drug development and multiregional clinical trials (MRCT): 5 years after implementation of ICH E17 guidelines. Ther Innov Regul Sci. 2024;58(5):845\u201354.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01069-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:47:57Z","timestamp":1792766877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":12,"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01069-w","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ito Furukawa is an employee of Sanofi. Mamoru Narukawa declares no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}